Avacta Group PLC has made an amendment to its Block Listing Six Monthly Return, correcting the figures for unallotted securities under its EMI and LTIP schemes. The corrected figures are 803,006 for the EMI scheme and 9,719,257 for the LTIP scheme. Avacta is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company has two divisions: Avacta Therapeutics, a clinical stage oncology biotech division, and Avacta Diagnostics, focused on supporting healthcare professionals and broadening access to diagnostics. Avacta's proprietary platforms, pre|CISION™ and Affimer®, are aimed at developing novel, highly targeted cancer drugs. The pre|CISION™ platform utilizes a highly specific substrate for fibroblast activation protein (FAP) to activate peptide and antibody/Affimer® drug conjugates in the tumor microenvironment, reducing systemic exposure and toxicity. For further information, Avacta can be contacted through the provided details.